US Patent

US10226423 — Colchicine drug-to-drug interactions

Formulation · Assigned to Rxomeg Therapeutics LLC · Expires 2037-12-20 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent describes the use of oral colchicine solutions in combination with other therapeutics while minimizing toxic interactions.

USPTO Abstract

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US10226423
Jurisdiction
US
Classification
Formulation
Expires
2037-12-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Rxomeg Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.